Comparison of an aggressive (U.S.) and a less aggressive (Canadian) policy for cholesterol screening and treatment.
暂无分享,去创建一个
C D Naylor | C. Naylor | M. Krahn | A. Detsky | A. Basiński | M Krahn | A S Basinski | A S Detsky | Murray Krahn | Allan S. Detsky | Antoni Basinski
[1] G. Oster,et al. Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease. The case of cholestyramine. , 1987, JAMA.
[2] A. Menotti,et al. Coronary risk factors and survival probability from coronary and other causes of death. , 1987, American journal of epidemiology.
[3] S. Leeder,et al. A cost‐effectiveness analysis of alternative strategies for the prevention of heart disease , 1988, The Medical journal of Australia.
[4] R B Haynes,et al. Increased absenteeism from work after detection and labeling of hypertensive patients. , 1978, The New England journal of medicine.
[5] Joseph S. Pliskin,et al. Utility Functions for Life Years and Health Status , 1980, Oper. Res..
[6] H. Hart,et al. Considerations of mortality in certain chronic diseases. , 1966, Annals of internal medicine.
[7] B. Kinosian,et al. Cutting into cholesterol. Cost-effective alternatives for treating hypercholesterolemia. , 1988, JAMA.
[8] G W Torrance,et al. Utility approach to measuring health-related quality of life. , 1987, Journal of chronic diseases.
[9] Daniel Steinberg,et al. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. , 1988, Archives of internal medicine.
[10] Moss Jm. Psychosocial consequences of labelling in hypertension. , 1981 .
[11] W. Browner. Estimating the impact of risk factor modification programs. , 1986, American journal of epidemiology.
[12] R. Lefebvre,et al. Labeling of participants in high blood pressure screening programs. Implications for blood cholesterol screenings. , 1988, Archives of internal medicine.
[13] D H Blankenhorn,et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. , 1987, JAMA.
[14] J. Huttunen,et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.
[15] S. Pauker,et al. The Markov Process in Medical Prognosis , 1983, Medical decision making : an international journal of the Society for Medical Decision Making.
[16] M. Alderman,et al. Hypertension control at the work site. , 1976, Journal of occupational medicine. : official publication of the Industrial Medical Association.
[17] A. Komaroff,et al. Cholesterol reduction and life expectancy. A model incorporating multiple risk factors. , 1987, Annals of internal medicine.
[18] J. C. Christiansen,et al. Impact of national guidelines for cholesterol risk factor screening. The Framingham Offspring Study. , 1989, JAMA.
[19] C. Naylor,et al. Asymptomatic hypercholesterolemia: a clinical policy review. , 1990 .
[20] D. Levy,et al. Cholesterol and mortality. 30 years of follow-up from the Framingham study. , 1987, JAMA.
[21] B. Lo,et al. Choice and use of blood lipid tests. An epidemiologic perspective. , 1983, Archives of internal medicine.
[22] G. Torrance,et al. The utility of different health states as perceived by the general public. , 1978, Journal of chronic diseases.
[23] A. Brett,et al. Treating hypercholesterolemia. How should practicing physicians interpret the published data for patients? , 1989, The New England journal of medicine.